Accelerate Diagnostics, Inc. Names Frank J. M. ten Brink to Board of Directors

Accelerate Diagnostics, Inc. Names Frank J. M. ten Brink to Board of Directors

PR Newswire

TUCSON, Ariz., March 6, 2013

TUCSON, Ariz., March 6, 2013 /PRNewswire/ --Accelerate Diagnostics, Inc.
(NASDAQ: AXDX), a developer of automated diagnostic systems for same-shift
identification and antibiotic resistance testing of bacterial and fungal
pathogens, announced today that Frank J.M. ten Brink has been appointed to its
board of directors.

Mr. ten Brink has more than 16 years of finance, accounting and merger &
acquisition experience in high-growth environments. He is currently serving as
executive vice president, chief financial officer and chief administrative
officer of Stericycle, Inc. (SRCL). Prior to joining Stericycle, he was senior
vice president and chief financial officer with Telular Corp. Between 1991 and
1995, he was vice president and chief financial officer of Hexacomb Corp.Mr.
ten Brink studied international business at the Netherlands School of Business
and the University of Oregon, where he received a master of business
administration degree in finance.

"We are privileged to have Frank join our board," commented John Patience,
Accelerate Diagnostic's chairman. "In addition to his extensive background in
finance and operations, his experience growing Stericycle from a $40 million
early-stage company to the $1.9 billion leader it is today will be invaluable
as we move forward."


Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in vitro diagnostics company
dedicated to providing solutions for the global challenge of drug resistant
organisms and hospital acquired infections. We are focused on developing and
commercializing innovative diagnostic systems for the rapid identification and
antibiotic susceptibility testing of infectious pathogens. The company's
revolutionary BACcel™ platform utilizes a proprietary culture-free process
with both genomic and phenotypic detection technologies that significantly
decreases time to result while achieving high sensitivity and specificity.

In addition to the BACcel system development pipeline, Accelerate Diagnostics
also owns and licenses its proprietary OptiChem® surface coatings technology,
which has numerous applications for binding in bio-analytical systems, such as


Certain statements in this news release may be "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Statements
regarding future prospects and developments are based upon current
expectations and involve certain risks and uncertainties that could cause
actual results and developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with the
Securities and Exchange Commission. Accelerate Diagnostics does not undertake
an obligation to publicly update or revise any forward-looking statements,
whether as a result of new information or future events.

SOURCE Accelerate Diagnostics, Inc.

Contact: Larry Mehren, Accelerate Diagnostics, Inc., President & CEO,
Press spacebar to pause and continue. Press esc to stop.